
Newsletter
|
|
Gian Paolo Andreoletti,
MD, Editor-in-Chief - paolo.andreoletti@senology.it |
|
www.senology.org /
www.senology.it Home Page |
|

Literature Selection
-
Thorpe H et al.: "Timing of breast cancer surgery in relation to
menstrual cycle phase: no effect on 3-year prognosis: The ITS
Study", Br J Cancer. 2007 Dec 18; [Epub ahead of print]
-
The Arimidex, Tamoxifen, Alone or in Combination (ATAC)
Trialists' Group: "Effect of anastrozole and tamoxifen as
adjuvant treatment for early-stage breast cancer: 100-month
analysis of the ATAC trial", Lancet Oncol. 2007 Dec 14; [Epub
ahead of print]
-
Buijs C et al.: "Prospective study of long-term impact of
adjuvant high-dose and conventional-dose chemotherapy on
health-related quality of life", J Clin Oncol. 2007 Dec 1;25(34):5403-9
-
Bertelsen L et al.: "Effect of
Systemic Adjuvant Treatment on Risk for Contralateral Breast
Cancer in the Women's Environment, Cancer and Radiation
Epidemiology Study", J Natl Cancer Inst. 2007 Dec 25; [Epub
ahead of print]
-
Miller K et al.: "Paclitaxel plus Bevacizumab versus Paclitaxel
Alone for Metastatic Breast Cancer", N Engl J Med. 2007 Dec 27;357(26):2666-2676
-
Bonnefoi H et al.: "Validation of
gene signatures that predict the response of breast cancer to
neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG
00-01 clinical trial", Lancet Oncol. 2007 Dec;8:1071-78
-
Jakesz R et al.: "Extended
Adjuvant Therapy With Anastrozole Among Postmenopausal Breast
Cancer Patients: Results From the Randomized Austrian Breast and
Colorectal Cancer Study Group Trial 6a", J Natl Cancer
Inst. 2007 Dec 11; DOI 10.1093/jnci/djm246
-
Bollet MA et al.: "Responses to concurrent radiotherapy and
hormone-therapy and outcome for large breast cancers in
post-menopausal women", Radiother Oncol. 2007 Dec;85(3):336-45
-
Miglioretti DL et al.: "Radiologist
Characteristics Associated With Interpretive Performance of
Diagnostic Mammography", J Natl Cancer Inst. 2007 Dec 11; [Epub
ahead of print]
Editorials
-
"Sarcomas of the breast" - Yazid Belkacémi,
Oscar Lambret Center, Lille, France; University of Lille II,
Lille, France
"The
Rare Cancer Network (www.rarecancer.net) study on
breast sarcoma is
the largest retrospective review of breast sarcomas published in the
literature. Data from 103 patients
have been collected in
a retrospective multicenter study.
The patients’ characteristics are similar to those reported in other
publications, according to sex-ratio, mean age at diagnosis, and tumour
size. Sarcoma of the breast is mainly a feminine tumour, and male cases
usually represent less than 5% of primary breast sarcomas. Mean age is
between 47 and 52 years, and mean tumour size is comprised
between 5.5 and 5.7 cm. In the literature, tumour size as well as
histological grade, which are classical prognostic factors of common
soft tissues sarcomas, were variably found to influence recurrence and
survival of sarcomas of the breast.
In our report, there
were 42 angiosarcomas. (...). In multivariate
analysis, favorable prognostic factors for local control were: no residual
tumor after treatment, no cellular pleomorphism, and histology other than
angiosarcoma. For disease-free survival, the five favorable prognostic factors were
non-menopausal status, no residual tumor after treatment, non-angiosarcoma
histology, absence of tumour necrosis, and grade 1-2 histology.
In
conclusion, angiosarcoma has a dramatical prognosis.
The outcome of the
other types of sarcomas may be worsened by residual tumor after
loco-regional therapy and high grade histology, a classical prognosis
factor of the other soft tissue sarcomas. In surgical procedure axillary
dissection is not mandatory". (Comment on paper:
Bousquet G et al.: "Outcome and prognostic factors in breast
sarcoma: A multicenter study from the rare cancer network",
Radiother Oncol. 2007 Dec;85(3):355-61)
Press Releases
30th
Annual San Antonio Breast Cancer Symposium
Healthcare Companies News
Calendar of Events

Literature Selection
-
Pollak KI et al.: "Oncologist communication about emotion during
visits with patients with advanced cancer", J Clin Oncol. 2007
Dec 20;25(36):5748-52
-
Oerlemans ME et al.: "A meta-analysis on depression and
subsequent cancer risk", Clin Pract Epidemol Ment Health. 2007
Dec 3;3(1):29
[Epub ahead of print]
-
Farooqui M et al.: "COX-2 inhibitor celecoxib prevents chronic
morphine-induced promotion of angiogenesis, tumour growth,
metastasis and mortality, without compromising analgesia", Br J
Cancer. 2007 Dec 3;97(11):1523-31
-
Chu TF et al.: "Cardiotoxicity associated with tyrosine kinase
inhibitor sunitinib", Lancet. 2007 Dec 15;370(9604):2011-9
-
van der Pols JC et al.: "Childhood dairy intake and adult cancer
risk: 65-y follow-up of the Boyd Orr cohort", Am J Clin Nutr.
2007 Dec;86(6):1722-9
-
Quasar Collaborative Group: "Adjuvant
chemotherapy versus observation in patients with colorectal
cancer: a randomised study", Lancet. 2007 Dec 15;370(9604):2020-9
-
Marinaccio A et al.: "Analysis of latency time and its
determinants in asbestos related malignant mesothelioma cases of
the Italian register", Eur J Cancer. 2007 Dec;43(18):2722-8
-
Edwards CG et al.: "Occupational
noise exposure and risk of acoustic neuroma", Am J Epidemiol.
2007 Dec 1;166(11):1252-8
-
de Crevoisier R et al.: "Exclusive
radiotherapy for primary squamous cell carcinoma of the vagina",
Radiother Oncol. 2007 Dec;85(3):362-70
-
Woodward ER et al.: "Annual
surveillance by CA125 and transvaginal ultrasound for ovarian
cancer in both high-risk and population risk women is
ineffective", BJOG. 2007 Dec;114(12):1500-9
-
Patz ER Jr et al.: "Panel of serum
biomarkers for the diagnosis of lung cancer", J Clin Oncol. 2007
Dec 10;25(35):5578-83
-
Pommier P et al.: "Is there a role
for pelvic irradiation in localized prostate adenocarcinoma?
Preliminary results of GETUG-01", J Clin Oncol. 2007 Dec 1;25(34):5366-73
-
Margulis V et al.: "Oncological
efficacy and safety of nephron-sparing surgery for selected
patients with locally advanced renal cell carcinoma", BJU Int.
2007 Dec;100(6):1235-9
Editorial
Press Releases
Clinical Guidelines
Video and Lectures
 Literature Selection
|
Educational
Grants - Sincere
appreciation is extended to the following companies
for their generous support of this activity:
- Roche
- AstraZeneca
If this e-mail
has reached you in error, simply click on the
following link and unsubscribe yourself:
Unsubscribe
Contact info - For
advertising information please contact:
A&B@senology.it
. For other
enquiries, problems or suggestions please contact:
staff@senology.it
©
A&B Edizioni Medico-Scientifiche - Bergamo, Italy.
Fax: +39.035.7171000 | |